Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,553 matching trials from the live ClinicalTrials.gov search.

Filters: Sacramento, California Clear all

Conditions: Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions: Testosterone Gel (1%); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 13 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions: Iron isomaltoside/ferric derisomaltose, Iron sucrose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 141
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material; Drug · Behavioral
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 51
States / cities: Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more

Conditions: Chronic Renal Failure, Chronic Kidney Disease
Interventions: Epoetin Hospira, Epogen Amgen; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 73
States / cities: Azusa, California • Bakersfield, California • Long Beach, California + 51 more

Conditions: BK Viremia; BKV DNAemia
Interventions: Anti-BK polyomavirus (AntiBKV); Biological
Lead sponsor: Memo Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 69
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: coagulation factor VIIa [recombinant]-jncw; Drug
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Ataluren; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 2 Years to 7 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more

Conditions: Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Radionuclide Imaging, Selpercatinib, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 172
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more

Conditions: Melanoma (Skin)
Interventions: interferon alfa-2b, observation; Biological · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2026
U.S. locations: 511
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 354 more

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more

Conditions: Breast Cancer
Interventions: Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Lung Cancer
Interventions: proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy, surgery; Genetic · Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 72
States / cities: Birmingham, Alabama • Concord, California • Duarte, California + 53 more

Conditions: Surgery
Interventions: Videolaryngoscopy review.; Other
Lead sponsor: University of California, Davis; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: brexucabtagene autoleucel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 14 more

Conditions: Acute Coronary Syndrome
Interventions: ADP receptor inhibitors; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 12,227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 185
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more

Conditions: Pulmonary Arterial Hypertension
Interventions: rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Epistaxis
Interventions: Tranexamic Acid, 0.9% Sodium Chloride; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Paroxysmal Atrial Fibrillation
Interventions: Cryoballoon ablation for the treatment of atrial fibrillation; Procedure
Lead sponsor: Sacramento EP Research; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Sacramento, California • Loveland, Colorado • Boston, Massachusetts + 1 more

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Carboplatin, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Relatlimab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 90
States / cities: Dublin, California • Fremont, California • Fresno, California + 69 more

Conditions: Psychosis, Clinical High Risk for Psychosis
Interventions: Mobile health application - Ginger.io; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 13 Years to 30 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Active Non-segmental Vitiligo
Interventions: PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 40
States / cities: Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more

Conditions: Growth Hormone Deficiency
Interventions: Genotropin, somatrogon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Sacramento, California • Aurora, Colorado • Centennial, Colorado + 11 more

Search by objective public record fields.

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

The PEARL 8.0 Post-Approval Study

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

Video-Assisted Laryngoscopy Education

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

Cryoballoon PVI With PWI Versus PVI Alone In Patients With PAF

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD